Volume 30, Number 5—May 2024
Dispatch
Protective Efficacy of Lyophilized Vesicular Stomatitis Virus–Based Vaccines in Animal Model
Table 2
Serologic evaluation of Lassa virus antibodies in immunized guinea pigs in study of protective efficacy of lyophilized vesicular stomatitis virus–based vaccines in an animal model*
| Animal group, n = 10 each | Median (range) | Average (SEM) | Fold increase† |
|---|---|---|---|
| Preimmunization | 1.4 (0.8–3.8) | 1.8 (0.4) | NA |
| Ly-VSV∆G/LASVGPC | 100.7 (8–373) | 148.6 (44.2) | 82 |
| VSV∆G/LASVGPC | 160.5 (79–262.8) | 172 (17.7) | 95 |
| Ly-VSV∆G/EBOVGP | 2 (0.7–6.1) | 2.4 (0.6) | 1.4 |
*Serum was analyzed for the presence of Lassa glycoprotein-specific antibodies by using an ELISA before challenge with Lassa virus. The standard curve was generated by using human control serum samples; therefore, values should be considered relative and for comparison purposes only. Ly-VSV∆G/EBOVGP, lyophilized vesicular stomatitis virus expressing Ebola virus glycoprotein; Ly-VSV∆G/LASVGPC, lyophilized vesicular stomatitis virus expressing Lassa virus glycoprotein; NA, not applicable; VSV∆G/LASVGPC, vesicular stomatitis virus expressing Lassa virus glycoprotein. †Fold change of average values from immunized animals compared with randomized preimmunization control specimens.